pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
argenx is a pharma organization headquartered in GENT, BE. Primary therapeutic focus areas include Generalized Myasthenia Gravis, Chronic inflammatory demyelinating polyneuropathy (CIDP), Bullous Pemphigoid, Thyroid Eye
33 Arch Street, Suite 3201, Boston, MA 02110, US HQ
2008 Founded
2,179 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
Placebo for efgartigimod, ARGX-113
Phase 3 · small molecule · Chronic Idiopathic thrombocytopenic purpura
Placebo for efgartigimod, ARGX-113 for Chronic Idiopathic thrombocytopenic purpura is a Phase 3 program (small_molecule) at argenx with 1 ClinicalTrials.gov record(s).
Internal code ARGX-113-2409
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- argenx
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Chronic Idiopathic thrombocytopenic purpura
- Status
- active
- Trials
- 1